Completed PHASE1 INTERVENTIONAL 1-arm NCT00858455

A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572 (DDI)

A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Maalox® Advanced Maximum Strength and One A Day® Maximum on Pharmacokinetics of GSK1349572 in Healthy Adult Subjects

Sponsor: GlaxoSmithKline

Conditions Healthy Volunteer

Interventions GSK1349572 GSK1349572 and Maalox Advanced Maximum Strength GSK1349572 and MaaloxAdvanced Maximum Strength GSK1349572 and One A Day

Updated 6 times since 2017 Last updated: Jun 4, 2009 Started: Jan 31, 2009 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00858455, this PHASE1 trial focuses on Healthy Volunteer and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Shionogi

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States